2022 World Conference on Lung Cancer (ePosters)-EP04.01-017. Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+ Non-small Cell Lung Cancer

EP04.01-017. Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+ Non-small Cell Lung Cancer

Back to course

Pdf Summary

This poster presents the cost-effectiveness of atezolizumab as adjuvant treatment for patients with stage II-IIIA PD-L1 non-small cell lung cancer (NSCLC). Atezolizumab demonstrated a significant disease-free survival benefit compared to best supportive care in clinical trials. The study used a Markov model to evaluate the cost-effectiveness of atezolizumab versus best supportive care. The model included costs associated with drug administration, radiation therapy, CT scans, and end-of-life care. The results showed that atezolizumab was cost-effective, with an incremental cost-effectiveness ratio (ICER) of $46,859 per quality-adjusted life-year (QALY) in the base case analysis. A scenario analysis using Medicare-specific costs also showed that atezolizumab was cost-effective in the Medicare population. One-way sensitivity analysis indicated that time to immunotherapy rechallenge in the metastatic health state was the most influential parameter in the model. The study has some limitations, including uncertainty around the extrapolation of disease-free survival beyond the trial follow-up period and the use of clinical inputs derived from the literature rather than directly from the clinical trial. However, the findings support the utilization of atezolizumab as the new standard of care for adjuvant treatment in resected patients with PD-L1 NSCLC.

Asset Subtitle

Millie Das

Meta Tag

Speaker Millie Das

Topic Global Health, Health Services Research, and Health Economics - Cost Issues

Keywords

atezolizumab

adjuvant treatment

stage II-IIIA

PD-L1 non-small cell lung cancer

disease-free survival

cost-effectiveness

Markov model

incremental cost-effectiveness ratio

quality-adjusted life-year

Medicare population